fig5

Figure 5. Administration of ADSC-EVs elevates the butyric acid level of intestinal contents and decreases the systemic inflammation in mice with LF. (A) Comparison of the butyric acid level in the cecal content from each group of mice (n = 8); (B) Representative images of MPO staining in the mouse colon tissues (scale bar: 200 µm); (C) The hepatic infiltrated MoMFs in mice with LF were analyzed by flow cytometry. The gating strategy for infiltrated inflammatory MoMFs was CD45⁺-Ly6G^--CD11c^--CD3^--CD11b⁺-F4/80^low-Ly6c^high and for infiltrated restorative MoMFs was CD45⁺-Ly6G^--CD11c^--CD3^--CD11b⁺-F4/80^low-Ly6c^low. Also, (D) the result was quantified by the ratio of Ly6C^high/Ly6C^low (n = 3). All data are shown as the mean ± SD. ^*P < 0.05; ^**P < 0.01. ADSC-EVs: Adipose-derived stem cell extracellular vesicles; LF: liver fibrosis; MPO: myeloperoxidase; MoMFs: monocyte-derived macrophages; SD: standard deviation; LF + EV: liver fibrosis + ADSC-EV group.